07:06 EDT Akero Therapeutics (AKRO) sees cash, equivalents funding operating plan into 2028
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- Promising Phase 2b Results for Akero Therapeutics’ Efruxifermin Highlight Potential for FDA Approval Despite Key Risk Score Challenges
- Promising Phase 2b Results and Future Prospects for Akero Therapeutics’ Efruxifermin Boost Buy Rating
- Akero Therapeutics announces new analyses of Phase 2b HARMONY trial
- Akero Therapeutics announces publication of Phase 2b SYMMETRY trial
- Akero Therapeutics reports results from Phase 2b SYMMETRY trial